Baseline Characteristics: Common Quality-Control Review Issues

Results Database Train-the-Trainer Workshop August 2021







Find the Error

Results Baseline Characteristics

Arm/Group Description		Ender-G, Low Dose	Ender-G, High Dose	Total
		5 mg tablet, twice daily	10 mg tablet, twice daily	Total of all reporting groups
Overall Number of Baseline Participants		103	99	202
Baseline Analysis Popula	tion Description			
Body Mass Index (BMI) Measure Type: Number Unit of measure: participants	Number Analyzed	103 participants	99 participants	202 participants
		22.5	23.1	22.8



Results Baseline Characteristics

Arm/Group Title	Ender-G, Low Dose	Ender-G, High Dose	Total
Arm/Group Description	5 mg tablet, twice daily	10 mg tablet, twice daily	Total of all reporting groups
Overall Number of Baseline Participants	103	99	202
Baseline Analysis Population Description			
Body Mass Index (BMI) Number Analyzed Measure Type: Number Unit of measure: participants	103 participants	99 participants	202 participants
	22.5	23.1	22.8



Results Baseline Characteristics

	Arm/Group Title	Ender-G, Low Dose	Ender-G, High Dose	Total
Body Mass Index (BMI) Measure Type: Number Unit of measure: participants	Number Analyzed	103 participants	99 participants	202 participants
		22.5	23.1	22.8

Comments [1]

Major Issues:

1) Information within the measure appears inconsistent.



Results Baseline Characteristics

Arm/Group Description		Ender-G, Low Dose 5 mg tablet, twice daily	Ender-G, High Dose 10 mg tablet, twice daily	Total Total of all reporting groups
Overall Number of Baseline Participants Baseline Analysis Population Description		103	99	202
Body Mass Index (BMI) Number Analyzed Mean (Full Range) Unit of measure: kg/m^2		103 participants	99 participants	202 participants
		22.5 (19 to 31)	23.0 (18 to 33)	22.8 (18 to 33)







Find the Error

Results Baseline Characteristics


	Arm/Group Title				
ECOG Performance Status	Number Analyzed	79 participants			
Measure Type: Count of Participants Unit of measure: participants					
0		48			
1		27			
2		4			

Results Baseline Characteristics

		Arm/Group Title	Remuverol
~	ECOG Performance Status	Number Analyzed	79 participants
1	Measure Type: Count of Participants Unit of measure: participants		
	0		48
	1		27
	2		4



Results Baseline Characteristics



NIH National Library of Medicine

Results Baseline Characteristics

	Remuverol	
ECOG Performance Status	Number Analyzed	79 participants
Measure Type: Count of Participants Unit of measure: participants		
0		48
1		27
2		4

ClinicalTrials.gov

Comments [1]

Major Issues:

1) The description of the scale or categories does not include sufficient information to understand the results reported.



Results Baseline Characteristics

	Arm/Group Title	Remuverol
Eastern Cooperative Oncology Group (ECOG) Performance Status ^[1] Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	79 participants
0 – Fully Active		48
1 – Ambulatory, Restricted Strenuous Activity		27
2 – Ambulatory, No Work Activities		4
		[1] Measure Description: Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects a participant's daily living abilities. The scale ranges from 0 (fully active) to 5 (dead). 0 = Fully active without restriction; 1 = Restricted in physically strenuous activity; 2 = Ambulatory, capable of all selfcare; 3 = Capable of limited selfcare; 4 = Completely disabled; 5 = Dead.







Find the Error

Results Participant Flow

Arm/Group Title	Cinacalcet	Placebo
Arm/Group Description	Participants received 80 mg/ml of Cinacalcet intravenously twice a day, for 12 weeks.	Participants received 80 mg/ml of Placebo intravenously twice a day, for 12 weeks.
Period Title: Overall Study	,	
Started	368	184
Completed	7	8
Not Completed	361	179

Results Baseline Characteristics

Arm/Group Title		Cinacalcet	Placebo	Total
Overall Number of Baseline Participants	Overall Number of Baseline Participants			
Age, Continuous ^[1] Mean (Standard Deviation) Unit of measure: Years	Number Analyzed	280	150	430
		58.5 ± 999	58.3 ± 999	$\textbf{58.4} \pm \textbf{999}$
			escription: 999 ir dard deviation w	

NIH National Library of Medicine

Results Participant Flow								
Arm/Group Title	Cinacalcet	Placeb	00					
Arm/Group Description	Participants received 80 mg/ml of Cinacalcet intravenously twice a day, for 12 weeks.	Participants re 80 mg/ml of Pl intravenously day, for 12 we	lacebo twice a					
Period Title: Overall Study								
Started	368	184						
Completed	7	8						
Not Completed	361	179		Results Baseline Characteristics	i			
				Arm/Group Title		Cinacalcet	Placebo	Total
			Overall	Number of Baseline Participants		280	150	430
			N	Age. Continuous ^[1] lean (Standard Deviation) Unit of measure: Years	Number Analyzed	280	150	430
						58.5 ± 999	58.3 ± 999	58.4 ± 999
							escription: 999 in dard deviation w	



Results Participant Flow

Arm/Group Title	Cinacalcet	Placebo
Arm/Group Description	Participants received 80 mg/ml of Cinacalcet intravenously twice a day, for 12 weeks.	Participants received 80 mg/ml of Placebo intravenously twice a day, for 12 weeks.
Period Title: Overall Study		
Started	368	184
Completed	7	8
Not Completed	361	179

Results Baseline Characteristics

	Arm/Group Title		Cinacalcet	Placebo	Total
	Overall Number of Baseline Participants		280	150	430
	Age, Continuous ^[1] Mean (Standard Deviation) Unit of measure: Years	Number Analyzed	280	150	430
2		>	58.5 ± 999	58.3 ± 999	58.4 ± 999
		\longrightarrow		escription: 999 in dard deviation w	
			Clinica	lTrials.gov	



Results Baseline Characteristics

Arm/Group Title		Cinacalcet	Placebo	Total
Overall Number of Baseline Participants		280	150	430
Age, Continuous ^[1] Mean (Standard Deviation) Unit of measure: Years	Number Analyzed	280	150	430
		58.5 ± 999	58.3 ± 999	58.4 ± 999
		^[1] Measure Description: 999 inserted because standard deviation was not calculated.		se standard

Comments [1]

Major Issues:

1) One or more numbers in the table appear to be nonmeaningful placeholders that do not reflect data collected during the study.



ClinicalTrials.gov

Results Participant Flow

Arm/Group Title	Cinacalcet	Placebo			
Arm/Group Description	Participants received 80 mg/ml of Cinacalcet intravenously twice a day, for 12 weeks.	Participants received 80 mg/ml of Placebo intravenously twice a day, for 12 weeks.			
Period Title: Overall Study	Period Title: Overall Study				
Started	368	184			
Modified Intention to Treat	280	150			
Completed	7	8			
Not Completed	361	179			

Results Baseline Characteristics

Arm/Group Title		Cinacalcet	Placebo	Total
Overall Number of Baseline Participants		280	150	430
Age, Continuous Mean (Standard Deviation) Unit of measure: Years	Number Analyzed	280	150	430
		58.5 ± 15.5	58.3 ± 14.5	58.4 ± 14.8







Find the Error

Results Participant Flow

Arm/Group Title	Sorafenib (Nexavar, BAY43-9006)
Arm/Group Description	Inpatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle, and 800 mg bid until disease progression, unacceptable toxicity, or withdrawal of consent. Each cycle is 28 days. Dose reductions due to toxicities were allowed.
Period Title: Cycle 1 (28 Day	/s)
Started	83
Completed	52
Not Completed	31
Period Title: Cycle 2 (28 Day	/S)
Started	52
Completed	44
Not Completed	8
Period Title: Cycle 3 (28 Day	/s)
Started	44
Completed	33
Not Completed	11

Results Baseline Characteristics

Arm/Group Title	Cycle 1, 400 mg	Cycle 2, 600 mg	≥Cycle 3, 800 mg	Total
Arm/Group Description	All participants who received the dose escalation of sorafenib 400 mg bid for the first cycle	All participants who received the dose escalation of sorafenib 600 mg bid for the second cycle	All participants who received the dose escalation of sorafenib 800 mg bid for the third and greater cycles	Total of all reporting groups
Overall Number of Baseline Participants	83	52	44	179
Age, Continuous Median (Full Range) Unit of measure: Years	61 (33 to 80)	63 (33 to 72)	55 (33 to 72)	61 (33 to 80)

Results Participant Flow

Arm/Group Title	Sorafenib (Nexavar, BAY43-9006)			
Arm/Group Description	Inpatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle, and 800 mg bid until disease progression, unacceptable toxicity, or withdrawal of consent. Each cycle is 28 days. Dose reductions due to toxicities were allowed.			
Period Title: Cycle 1 (28 Days)				
Started		83		
Completed		52		
Not Completed	31			
Period Title: Cycle 2 (28 Day	ys)			
Started		52		
Completed		44		
Not Completed	8			
Period Title: Cycle 3 (28 Day	ys)			
Started		44		
Completed		33		
Not Completed		11		

Results Baseline Characteristics

Arm/Group Title	Cycle 1, 400 mg	Cycle 2, 600 mg	≥Cycle 3, 800 mg	Total
Arm/Group Description	All participants who received sorafenib 400 mg bid for the first cycle	All participants who received the dose escalation of sorafenib 600 mg bid for the second cycle	All participants who received the dose escalation of sorafenib 800 mg bid for the third and greater cycles	Total of all reporting groups
Overall Number of Baseline Participants	83	52	44	179
Age, Continuous Median (Full Range) Unit of measure: Years	61 (33 to 80)	63 (33 to 72)	55 (33 to 72)	61 (33 to 80)

Results Baseline Characteristics

Arm/Group Title Arm/Group Description		Cycle 1, 400 mg All participants who received the dose escalation of sorafenib 400 mg bid for the first cycle	Cycle 2, 600 mg All participants who received the dose escalation of sorafenib 600 mg bid for the second cycle	≥Cycle 3, 800 mg All participants who received the dose escalation of sorafenib 800 mg bid for the third and greater cycles	Total Total of all reporting groups
Overall Number of Baseline Participants		83	52	44	179
Baseline Analysis Population Description			,		
Age, Continuous Median (Full Range) Unit of measure: Years	Number Analyzed	83	52	44	179
		61 (33 to 80)	63 (33 to 72)	55 (33 to 72)	61 (33 to 80)

Comments [1]

Major Issues:

1) Participants appear to be counted more than once within a row.



Results Participant Flow

Arm/Group Title	Sorafenib (Nexavar, BAY43-9006)		
Arm/Group Description	Inpatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle, and 800 mg bid until disease progression, unacceptable toxicity, or withdrawal of consent. Each cycle is 28 days. Dose reductions due to toxicities were allowed.		
Period Title: Cycle 1 (28 Days)			
Started	83		
Completed	52		
Not Completed	31		
Period Title: Cycle 2 (28 Days)			
Started	52		
Completed	44		
Not Completed	8		
Period Title: Cycle 3 (28 Days)			
Started	44		
Completed	33		
Not Completed	11		

Results Baseline Characteristics

	Sorafenib (Nexavar, BAY43-9006)						
Arm/Group Description		Inpatient dose escalation of sorafenib from 400 mg orally					
Overall	Number of Participants	83					
Age, Continuous ^[1] Median (Full Range) Unit of measure: Years							
Cycle 1	Number Analyzed	83 participants					
		61 (33 to 80)					
Cycle 2	Number Analyzed	52 participants					
		63 (33 to 72)					
Cycle 3	Number Analyzed	44 participants					
		55 (33 to 72)					
		 [1] Measure Analysis Population Description: Not all participants continued to cycles 2 and 3. 					





Find the Error

Results Baseline Characteristics

	Arm/Group Title	Mycophenolate Mofetil + Sirolimus	Mycophenolate Mofetil + Cyclosporine or Tacrolimus	Total
	Arm/Group Description	Mycophenolate mofetil orally twice daily at a	Mycophenolate mofetil orally twice	Total of all reporting groups
Overall Number of Baseline Participants		151	154	305
Age, Categorical Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	151	154	305
	<=18 years	0	0	0
	Between 18 and 65 years	102	106	208
	>=65 years	49	48	97
Age, Customized Mean (Standard Deviation) Unit of measure: years	Number Analyzed	151	154	305
		48.7 (12.9)	48.9 (12.7)	NA (NA) ^[1]
		[1] Age was not calc	ulated for the total p	population.



1

Results Baseline Characteristics

Arm/Group Title		Mycophenolate Mofetil + Sirolimus	Mycophenolate Mofetil + Cyclosporine or Tacrolimus	Total
		Mycophenolate mofetil orally twice daily at a	Mycophenolate mofetil orally twice	Total of all reporting groups
Overall Number of Baseline Participants		151	154	305
Age, Categorical Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	151	154	305
	<=18 years	0	0	0
	Between 18 and 65 years	102	106	208
	>=65 years	49	48	97
Age, Customized Mean (Standard Deviation) Unit of measure: years	Number Analyzed	151	154	305
		48.7 (12.9)	48.9 (12.7)	NA (NA) ^[1]
	[1] Age was not calculated for the total population.			



Results Baseline Characteristics

	Arm/Group Title	Mycophenolate Mofetil + Sirolimus	Mycophenolate Mofetil + Cyclosporine or Tacrolimus	Total
Arm/Group Description		Mycophenolate mofetil orally twice daily at a	Mycophenolate mofetil orally twice	Total of all reporting groups
Overall Number of Baseline Participants	151	154	305	
Age, Categorical Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	151	154	305
	<=18 years	0	0	0
	Between 18 and 65 years	102	106	208
	>=65 years	49	48	97
Age, Customized Mean (Standard Deviation) Unit of measure: years	Number Analyzed	151	154	305
		48.7 (12.9)	48.9 (12.7)	NA (NA) ^[1]
		[1] Age was not calculated for the total population.		



	Results Baseline Characteristics					
-		Mycophenolate Mofetil + Sirolimus	Mycophenolate Mofetil + Cyclosporine or Tacrolimus	Total		
	· · ·		Mycophenolate mofetil orally twice daily at a	Mycophenolate mofetil orally twice		
	Overall Number of Baseline Participants		151	154	305	
	Age, Categorical Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	151	154	305	
		<=18 years	0	0	0	
		Between 18 and 65 years	102	106	208	
		>=65 years	49	48	97	
	Age, Customized Mean (Standard Deviation) Unit of measure: years	Number Analyzed	151	154	305	
			48.7 (12.9)	48.9 (12.7)	NA (NA) ^[1]	
			[1] Age was not coloulated for the total population			

[1] Age was not calculated for the total population.

Comments [1]

Major Issues:

1) The explanation provided is not sufficient to understand why one or more values are not available.





Results Baseline Characteristics

	Arm/Group Title	Mycophenolate Mofetil + Sirolimus	Mycophenolate Mofetil + Cyclosporine or Tacrolimus	Total
	Arm/Group Description	Mycophenolate mofetil orally twice daily at a	Mycophenolate mofetil orally twice	Total of all reporting groups
Overall Number of Baseline Participants		151	154	305
Age, Categorical Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	151	154	305
	<=18 years	0	0	0
	Between 18 and 65 years	102	106	208
	>=65 years	49	48	97
Age, Continuous Mean (Full Range) Unit of measure: years	Number Analyzed	151	154	305
		48.7 (31 to 69)	48.9 (33 to 71)	48.8 (31 to 71)

